Table 1 Baseline characteristics of training and validation samples
From: Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer
Variables | Training sample | Validation sample | p value |
|---|---|---|---|
No. of patients | 361 | 102 | Â |
Age, years (mean, SD) | 71.43 (8.68) | 70.39 (8.17) | 0.309** |
PSA, ng/mL (median, IQR) | 253.8 (728.3-1349.7) | 358.0 (652.0-1597.2) | 0.779** |
≤T3, T4 (%) | 81.1, 18.9 | 62.8, 37.2 | <0.0001* |
EOD 1, 2, 3, 4 (%) | 40.7, 26.6, 25.5, 7.2 | 35.3, 27.5, 28.4, 8.8 | 0.764* |
Gleason ≤6, 7, 8-10 (%) | 6.4, 18.6, 75.0 | 3.0, 16.7, 80.3 | 0.189* |
Use of docetaxel (%) | 19.1 | 35.3 | <0.0001* |
Observation period, years (median, IQR) | 3.11 (3.11-4.15) | 2.58 (2.58-3.51) | 0.027** |